Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions

Clinical Cancer Research

Volumn 3, Issue 3, 1997, Pages 373-379

  Perez Soler, Roman ^a,b   Shin, Dong M ^a   Siddik, Zahid H ^a   Murphy, William K ^a   Huber, Martin ^a   Lee, Jin Soo ^a   Khokhar, Abdul R ^a   Hong, Waun K ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; PLATINUM 1,2 DIAMINOCYCLOHEXANE BISNEODECANOATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; FEMALE; HUMAN; INTRATUMORAL DRUG ADMINISTRATION; LUNG ADENOCARCINOMA; MALE; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PLEURISY; PRIORITY JOURNAL; REGIONAL PERFUSION; THORAX PAIN;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; FEMALE; HUMANS; LIPOSOMES; LUNG NEOPLASMS; MALE; MESOTHELIOMA; METABOLIC CLEARANCE RATE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PLEURA; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; RATS;

EID: 0030928461     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. De Vita, V. T., Hellman, S., and Rosenberg, S. A. (eds.), Cancer: Principles & Practice of Oncology, Ed. 4, pp. 1489-1508. Philadelphia: J. B. Lippincott Company, 1993.
2. Antman, K. H. Clinical presentation and natural history of benign and malignant mesothelioma. Semin. Oncol., 8: 313, 1981.
3. Walker-Renard, P., Leigh, M., Vaughan, M., et al. Chemical pleurodesis for malignant pleural effusions. Ann. Intern. Med., 120: 56-64, 1994.
4. Rusch, V., Saltz, L., Venkatraman, E., et al. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J. Clin. Oncol., 12: 1156-1163, 1994.
5. Markman, M., Cleary, S., King, M. E., and Howell, S. B. Cisplatin and cytarabine administered intrapleurally as treatment of malignant pleural effusions. Med. Pediatr. Oncol., 13: 191-193, 1985.
6. Rush, V. W., Figlin, R., Godwin, D., and Piantadosi, S. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group Trial. J. Clin. Oncol., 9: 313-319, 1991.
7. Jones, J. M., Olman, E. A., Egorin, M. J., and Aisner, J. A case report and description of the pharmacokinetic behaviour of intrapleurally instilled etoposide. Cancer Chemother. Pharmacol., 14: 172-174, 1985.
8. Howell, S. B., Chu, B. B. F., Wung, W. E., et al. Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant pleural effusions. J. Clin. Invest., 67: 1161-1170, 1981.
9. Ostrowski, M. J., and Halsall, G. M. Intracavitary bleomycin in the management of malignant effusions: a multicenter study. Cancer Treat. Rep., 66: 1903-1907, 1982.
10. Rush, V. W., Niedzwiecki, D., Tao, Y., et al. Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies. J. Clin. Oncol., 10: 1001-1006, 1992.
11. Perez-Soler, R., Khokhar, A. R., and Lopez-Berestein, G. Treatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato-1,2-trans-1,2-trans-R,R-diaminocyclohexane platinum(II) entrapped in multilamellar vesicles. Cancer Res., 47: 6462-6466, 1987.
12. Perez-Soler, R., Yang, L. Y., Drewinko, B., Lautersztain, J., and Khokhar, A. R. Increased cytotoxicity and reversal of resistance to cisplatin with entrapment of cis-bis-neodecanoato-l, 2-trans-R,R-diaminocyclohexane platinum(II) in multilamellar lipid vesicles. Cancer Res., 48: 4509-4512, 1988.
13. Perez-Soler, R., Lopez-Berestein, G., Lautersztain, J., Al-Baker, S., Francis, K., Macias-Kiger, D., Raber, M. N., and Khokhar, A. R. Phase I clinical and pharmacology study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II). Cancer Res., 50: 4254-4259, 1990.
14. Man, I., Ling, Y. H., Al-Baker, S., Khokhar, A. R., and Perez-Soler, R. Cellular pharmacology of liposomal-cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) (L-NDDP) and cisplatin in A2780 and A2780/PDD cells. Cancer Res., 53: 4913-4919, 1993.
15. Han, I., Khokhar, A. R., and Perez-Soler, R. Cellular accumulation and DNA damage induced by liposomal cis-bis-neodecanoatotrans-R,R-1,2-diamino-cyclohexane platinum(II) (L-NDDP) in LoVo and LoVo/ PDD cells. Anticancer Drugs, 5: 64-68, 1994.
16. Han, I., Ling, Y. H., Al-Baker, S., Khokhar, A. R., and Perez-Soler, R. Apoptosis induced by L-NDDP and cisplatin in A2780 and A2780/CP human ovarian carcinoma cells. Anticancer Res., 14: 421-426, 1994.
17. Perez-Soler, R. Liposomes as carriers of antitumor agents. Cancer Treat. Rev., 16: 67-82, 1989.
18. Delgado, G., Potkul, R. K., Treat, J. A., Lewandowski, G. S., Barter, J. F., Frost, D., and Rahman, A. A phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer. Am. J. Obstet. Gynecol., 160: 812-819, 1989.
19. Vadiei, K., Siddik, Z. H., Khokhar, A. R., Al-Baker, S., Sampedro, F., and Perez-Soler, R. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin administered i.v. and i.p. in the rat. Cancer Chemother. Pharmacol., 30: 365-369, 1992.
20. Cooper, E. R., and Berner, B. Penetration enhancers. In: Kydonieus A. F. and B. Berber (eds.), Transdermal Delivery of Drugs, Vol. II. Boca Raton, FL: CRC Press, 1987.
21. Perez-Soler, R., Francis, K., Al-Baker, S., et al. Preparation and characterization of a liposomal preparation containing a lipophilic cisplatin derivative for clinical use. J. Microencapsulation. 11: 41-54, 1994.
22. Siddik, Z. H., Perez-Soler, R., Khokhar, A. R., Pazdur, R., Roh, M. S., Francis, K., Chase, J., and Krakoff, I. H. Clinical pharmacokinetics of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) (L-NDDP). Proc. Annu. Meet. Am, Assoc. Cancer Res., 32: 176, 1991.
23. Albers, A. S., Falkson, F., Goodhals, L., Vorobiof, D., and Vander Merwe, C. Malignant pleural mesothelioma: a disease unaffected by current therapeutic measures. J. Clin. Oncol., 6: 527-535, 1988.
24. Aisner, J., and Wiernick, P. H. Chemotherapy in the treatment of malignant mesothelioma. Semin. Oncol., 8: 335-343, 1981.
25. Howell, S, B., Zimm, S., Markman, M., et al. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J. Clin. Oncol., 5: 1607-1612, 1987.
26. Beller, U., Speyer, J., Colombo, N., et al. Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer. J. Clin. Oncol., 9: 809-817, 1991.
27. Alberts, D. S., Liu, P. Y., Hannigan, E. V., et al. Phase III study of i.p. cisplatin (CDDP)/i.v. cyclophosphamide (CPA) vs. i.v. CDDP/i.v. CPA in patients with optimal disease stage III ovarian cancer: a SWOGGOG-ECOG intergroup study (INT 0051). Proc. Am. Soc. Clin. Oncol., 14: 273, 1995.
28. Zimm, S., Cleary, S., Lucas, W., et al. Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. Cancer Res., 47: 1712-1716, 1987.
29. Los, G., Verdegaal, E. M. E., Mutsaer, P. H. A., McVie, J. G. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother. Pharmacol., 28: 159-165, 1991.
30. Shin, D. M., Umsawadi, T., Fossella, F. V., Murphy, W. K., Chasen, M. H., Walsh, G. L., Putnam, J. B., McMurtrey, M. J., and Hong, W. K. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer (Phila.), in press, 1997.
31. Walsh, G. L., Shin, D. M., Komaki, R., McMurtrey, M. J., Hong, W. K., and Roth, J. A. An aggressive multimodality protocol does not improve survival in patients with malignant pleural mesothelioma. 1994 Annual Meeting of the Society of Surgical Oncology, Houston, TX, 1994.